On the evening of March 3, the company announced that Shanghai Langmai, a wholly-owned subsidiary, won the bid for the first phase of the EPC package for the production of therapeutic monoclonal antibodies in Shaxian County of Amabo Biomedical Company, with a total order value of 162 million yuan. Comment: Maintaining the Overweight Rating. In view of the accelerated release of the company's downstream orders, maintaining the company's 2015-2017 EPS forecast of 0.20/0.27/0.33 yuan, the implementation of Langmai's large order dispels market doubts about the future growth of this field. At the same time, as the fixed increase nears the end, epitaxial expansion will accelerate implementation, maintaining a target price of 15 yuan, space of 53%, and an increase in holding ratings. The growth potential of Shanghai Langmai has been further determined. The market previously worried that Shanghai Langmai's future growth will gradually decline as the peak GMP certification period passes, but through grassroots research, we believe that the company's order capacity in the field of new drugs and modifications is strong, and future growth is still high. The current order is 162 million, accounting for more than 30% of the estimated revenue for the full year of 2015, further enhancing the certainty of the company's future performance. At the same time, it entered the hospital clean area business through the acquisition of 80% of Sichuan Chenxi's shares, so as to plan ahead and enhance long-term growth through synergy. Defining the final stage, the focus of the next phase may be on specialist hospitals. The fixed increase of 7.88 yuan/share will come to an end. We expect the company's next phase to focus on extended expansion. The company announced, “In terms of health services, we will actively participate in local hospital reform and focus on specialty hospitals.” We expect that the company's layout direction in the “big health” field will become more clear, and the implementation of the project is expected to accelerate. Risk warning: The risk of delaying M&A projects.